THE NEW ENGLAND life sciences industry has produced an explosion of therapies for small patient populations with rare diseases. Last year, fully half of newly approved drugs were for these […]
THE NEW ENGLAND life sciences industry has produced an explosion of therapies for small patient populations with rare diseases. Last year, fully half of newly approved drugs were for these […]